GoAI
Get started
Alibaba Health Information Technology Limited logo

Alibaba Health Information Technology Limited

0241.HK

HKSEHealthcareMedical - Healthcare Information Services

Open in GoAI

Latest quote

HK$3.14

−HK$0.12 · -3.68%

Aug 24, 4:08 PM HKT

0241.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; asset management; network hospital, software technical services, healthcare related internet information and technical services and research; operation of internet hospitals, as well as Alibaba Health, flagship platform of Alibaba Group for integrated online and offline medical and healthcare resources, providing one-stop healthcare solutions. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
HK
CEO
Di Fan Shen
Listed since
Mar 22, 2004
Employees
1,394

Market position

Day range

Current HK$3.14

52-week range

Current HK$3.14

Open
HK$3.245
Previous close
HK$3.26
Volume
99.37M
0.92× average
Average volume
108.2M
Average daily volume
Market cap
50.79B HKD
Beta
1.61
Market reference 1
50-day average
HK$3.3832
-7.19% below average
200-day average
HK$4.7578
-34.00% below average

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score
8.03
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends27%15%4%-8%Gross margin, FY2022: 19.96%Gross margin, FY2023: 21.30%Gross margin, FY2024: 21.81%Gross margin, FY2025: 24.29%Gross margin, FY2026: 23.97%Operating margin, FY2022: -5.34%Operating margin, FY2023: -0.12%Operating margin, FY2024: 2.65%Operating margin, FY2025: 5.15%Operating margin, FY2026: 5.36%Net margin, FY2022: -1.29%Net margin, FY2023: 2.00%Net margin, FY2024: 3.27%Net margin, FY2025: 4.68%Net margin, FY2026: 5.65%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 19.96%. Gross margin FY2023 21.30%. Gross margin FY2024 21.81%. Gross margin FY2025 24.29%. Gross margin FY2026 23.97%. Operating margin FY2022 -5.34%. Operating margin FY2023 -0.12%. Operating margin FY2024 2.65%. Operating margin FY2025 5.15%. Operating margin FY2026 5.36%. Net margin FY2022 -1.29%. Net margin FY2023 2.00%. Net margin FY2024 3.27%. Net margin FY2025 4.68%. Net margin FY2026 5.65%.

Income trends

Revenue

34.26B CNY+11.95%

Operating income

1.84B CNY+16.50%

Net income

1.94B CNY+35.17%
Income trends across reported periods37.79B CNY23.65B CNY9.51B CNY−4.63B CNYRevenue, FY2022: 20.58B CNYRevenue, FY2023: 26.76B CNYRevenue, FY2024: 27.03B CNYRevenue, FY2025: 30.6B CNYRevenue, FY2026: 34.26B CNYOperating income, FY2022: −1.1B CNYOperating income, FY2023: −31.79M CNYOperating income, FY2024: 717.4M CNYOperating income, FY2025: 1.58B CNYOperating income, FY2026: 1.84B CNYNet income, FY2022: −265.56M CNYNet income, FY2023: 535.65M CNYNet income, FY2024: 883.48M CNYNet income, FY2025: 1.43B CNYNet income, FY2026: 1.94B CNYFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 20.58B CNY. Revenue FY2023 26.76B CNY. Revenue FY2024 27.03B CNY. Revenue FY2025 30.6B CNY. Revenue FY2026 34.26B CNY. Operating income FY2022 −1.1B CNY. Operating income FY2023 −31.79M CNY. Operating income FY2024 717.4M CNY. Operating income FY2025 1.58B CNY. Operating income FY2026 1.84B CNY. Net income FY2022 −265.56M CNY. Net income FY2023 535.65M CNY. Net income FY2024 883.48M CNY. Net income FY2025 1.43B CNY. Net income FY2026 1.94B CNY.
Metric (CNY)FY2026FY2025FY2024FY2023FY2022
Revenue34.26B CNY30.6B CNY27.03B CNY26.76B CNY20.58B CNY
Cost of goods sold26.05B CNY23.17B CNY21.13B CNY21.06B CNY16.47B CNY
Gross profit8.21B CNY7.43B CNY5.9B CNY5.7B CNY4.11B CNY
Research and development788.35M CNY720.05M CNY705.38M CNY677.82M CNY728.83M CNY
Selling, general, and administrative2.83B CNY2.65B CNY2.14B CNY2.15B CNY2.38B CNY
Operating expenses6.37B CNY5.86B CNY5.18B CNY5.65B CNY5.13B CNY
Interest income447.15M CNY464.85M CNY478.03M CNY331.59M CNY209.76M CNY
Interest expense1.35M CNY2.61M CNY5.97M CNY5.83M CNY3.82M CNY
Depreciation and amortization30.79M CNY57.61M CNY53.68M CNY27.03M CNY60.58M CNY
Operating income1.84B CNY1.58B CNY717.4M CNY−31.79M CNY−1.1B CNY
Net income1.94B CNY1.43B CNY883.48M CNY535.65M CNY−265.56M CNY

Company facts updated Aug 24, 2026.

Corporate actions

Corporate action history

Dividend

Ex-dividend Aug 12, 2026

HK$0.2249

Special

Record Aug 13, 2026 · Payment Sep 2, 2026

0241.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

ETFs holding 0241.HK

Funds reporting this stock among their holdings, ordered by reported position size.

KraneShares CSI China Internet ETF logoKraneShares CSI China Internet ETFKWEB
Market value
85.4M
Weight
1.61%
AUM
5.3B USD
Expense ratio
0.69%
Price / 1D
$26.165-1.86%
Vanguard Total International Stock ETF logoVanguard Total International Stock ETFVXUS
Market value
40.69M
Weight
0.01%
AUM
646.2B USD
Expense ratio
0.05%
Price / 1D
$87.31-0.46%
Vanguard FTSE Emerging Markets ETF logoVanguard FTSE Emerging Markets ETFVWO
Market value
38.78M
Weight
0.02%
AUM
162.3B USD
Expense ratio
0.06%
Price / 1D
$59.9999-0.74%
iShares Core MSCI Emerging Markets ETF logoiShares Core MSCI Emerging Markets ETFIEMG
Market value
24.74M
Weight
0.02%
AUM
160B USD
Expense ratio
0.09%
Price / 1D
$80.685-1.08%
Vanguard FTSE All-World ex-US ETF logoVanguard FTSE All-World ex-US ETFVEU
Market value
6.36M
Weight
0.01%
AUM
95.9B USD
Expense ratio
0.04%
Price / 1D
$85.30-0.46%
iShares MSCI Emerging Markets ETF logoiShares MSCI Emerging Markets ETFEEM
Market value
5.54M
Weight
0.02%
AUM
31.22B USD
Expense ratio
0.72%
Price / 1D
$66.24-1.31%
iShares ESG Aware MSCI EM ETF logoiShares ESG Aware MSCI EM ETFESGE
Market value
5.34M
Weight
0.08%
AUM
6.91B USD
Expense ratio
0.25%
Price / 1D
$53.275-1.21%
iShares MSCI China ETF logoiShares MSCI China ETFMCHI
Market value
5.33M
Weight
0.08%
AUM
6.29B USD
Expense ratio
0.59%
Price / 1D
$54.885-1.39%

Continue in GoAI

Research 0241.HK

research.disclaimer